Our laboratory focuses on three major research themes that crosscut mitochondrial biology and translational science.
Establishing the global prevalence and genetic architecture of mitochondrial diseases
Development of large, deeply phenotyped and genetically stratified patient cohorts have significantly advanced understanding of the molecular and phenotypic spectrum for many mitochondrial diseases. However, substantial gaps in knowledge concerning global and population-specific variations in clinical presentation and genotypic distribution remain. As part of the International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD), a neuromuscular diseases transcontinental genomics research and capacity building partnership led by Professor Mike Hanna, we are working with collaborators across five continents to establish the global prevalence and genotype-phenotype architecture of mitochondrial diseases. This will enable better understanding of disease mechanisms, thereby facilitating the development of new treatments, and help establish trial-ready mitochondrial disease patient cohorts.
Understanding the role of cardiolipin in mitochondrial health and disease
Phospholipids are the major component of all cell membranes. Their amphiphilic properties enable formation of lipid bilayers that compartmentalise cells, thereby segregating metabolic pathways within highly specialised organelles. Cardiolipin is a non-bilayer phospholipid present exclusively in mitochondrial membranes that has many important roles necessary for normal mitochondrial function. Mammalian cardiolipin biosynthesis is a complex process that involves the endoplasmic reticulum and mitochondria, but it is ultimately synthesised from phosphatidic acid within the inner mitochondrial membrane. The intrinsic functional relationship between the endoplasmic reticulum and mitochondria has recently extended to mitochondrial division and mtDNA replication, which occurs at ER-mitochondria contact sites. We are studying the role of cardiolipin in these aspects of mitochondrial function using cell biology and imaging techniques, harnessing patient-derived induced pluripotent stem cell models, while attempting to identify new human disease-causing genes involved in phospholipid and cardiolipin metabolism.Generating effective therapies for mitochondrial diseases
Drug repurposing strategies explore the pharmacologic action of a known drug for an indication different from licensed. However, possible improved bioavailability of repurposed compounds through changes to their dose or route of administration is often overlooked before commencing efficacy trials. Numerous vitamins, cofactors and food supplements have significant repurposing potential in mitochondrial diseases but their target tissue engagement can be poor. One such example is nicotinamide riboside (NR), a Vitamin B3 derivative and NAD+ precursor, which has proven benefits in mouse models of mitochondrial disease via enhanced mitochondrial biogenesis. We are exploring a breadth of formulation technologies to design effective delivery systems for NR, and other NAD+ precursors, to maximize tissue penetration, harnessing myogenic differentiation of induced pluripotent stem cells derived from fibroblasts of patients with genetically confirmed mitochondrial disease to evaluate the efficacy of lead formulations in preclinical and proof-of-concept studies.
Collaborations
UCL:
UK:
International:
- National Institutes of Health (NIH), USA
- John Hopkins University, Baltimore, USA
- Max Planck Institute for Biology of Ageing, Cologne, Germany
- International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD)
- CSIR-Centre for Cellular and Molecular Biology, Hyderabad, India
- Nizam’s Institute of Medical Sciences, Hyderabad, India
- All India Institute of Medicine Science, New Delhi, India
- National Institute of Mental Health and Neurosciences, Bengaluru, India
- Columbia University, New York, USA
- Pontificia Universidad Católica de Chile, Chile
Close
